Plecanatide vs REGN1033
Head-to-head comparison of Plecanatide (Plecanatide) and REGN1033 (Trevogrumab (REGN1033)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | REGN1033 |
|---|---|---|
| Category | Gastrointestinal | Muscle & Performance |
| Full Name | Plecanatide | Trevogrumab (REGN1033) |
| Molecular Weight | Approx. 1620 Da | ~150 kDa |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | ~2-3 weeks |
| Amino Acids | 16 | N/A |
| Typical Dose | 3 mg once daily | 100-300 mg SC or equivalent trial dosing |
| Route | Oral | Subcutaneous / Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 60 |
| Research Status | Clinical | Clinical |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
REGN1033 Benefits
- ✓myostatin blockade
- ✓lean-mass preservation
- ✓muscle hypertrophy support
- ✓catabolic-state countermeasure
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
REGN1033 Dosing
SC or IV clinical-trial dosing|repeat every 2-4 weeks|dose escalation by study
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
REGN1033 Side Effects
- ⚠injection-site reactions
- ⚠headache
- ⚠fatigue
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
REGN1033
Human and animal studies indicate that myostatin neutralization can increase muscle size, though functional gains are often smaller than mass gains. Trevogrumab is part of the broader literature showing that selective myostatin inhibition can alter body composition in clinically meaningful ways.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.